The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
germ cell tumors
metastatic disease
neutrophil-to-lymphocyte ratio
prognosis
testicular cancer
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
21 12 2020
21 12 2020
Historique:
received:
30
07
2020
revised:
03
12
2020
accepted:
15
12
2020
entrez:
24
2
2021
pubmed:
25
2
2021
medline:
25
9
2021
Statut:
epublish
Résumé
We investigated the prognostic utility of pre-chemotherapy neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors (GCTs) undergoing first-line chemotherapy. We utilized two institutional databases to analyze the pretreatment-derived NLR (dNLR). Predictive accuracy was evaluated using the Cox proportional hazard model adjusted for the international germ cell cancer collaborative group (IGCCCG) risk classification. Discriminatory accuracy was evaluated by determining the area under the receiver operating characteristic curve (AUROC). In total, 569 of 690 patients had available dNLR (IGCCCG: good, 64%; intermediate, 21%; poor, 16%). The 5-year and 10-year overall survivals (OSs) for good, intermediate, and poor risk groups were 96.2%, 92.8%, and 62.7% and 93.9%, 90.3%, and 62.7%, respectively. A dNLR of 2 provided the best discriminatory accuracy with an AUROC of 0.58 (95% CI: 0.52-0.65,
Identifiants
pubmed: 33622996
pii: curroncol28010014
doi: 10.3390/curroncol28010014
pmc: PMC7816171
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-114Références
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Trends Immunol. 2009 Nov;30(11):522-30
pubmed: 19775938
Ann Oncol. 2016 May;27(5):875-9
pubmed: 26861605
J Clin Oncol. 2016 Mar 1;34(7):714-20
pubmed: 26786931
Br J Cancer. 2018 Mar 20;118(6):831-838
pubmed: 29485980
Bladder Cancer. 2016 Jul 27;2(3):351-360
pubmed: 27500202
Turk J Urol. 2017 Mar;43(1):55-61
pubmed: 28270952
Lancet Oncol. 2013 May;14(6):e218-28
pubmed: 23639322
Ann Oncol. 2016 Apr;27(4):732-8
pubmed: 26802161
Front Biosci (Schol Ed). 2010 Jan 01;2:176-83
pubmed: 20036938
Tumour Biol. 2016 Sep;37(9):11553-11572
pubmed: 27260630
Clin Genitourin Cancer. 2017 Apr;15(2):306-312.e3
pubmed: 27594554
Eur Urol. 2017 Feb;71(2):290-298
pubmed: 27649970
J Immunol. 1987 Oct 1;139(7):2406-13
pubmed: 2821114
Future Oncol. 2010 Jan;6(1):149-63
pubmed: 20021215
J Natl Cancer Inst. 1999 May 19;91(10):839-46
pubmed: 10340903
Eur J Cancer. 2006 May;42(7):820-6
pubmed: 16574403
Br J Cancer. 2012 Aug 7;107(4):695-9
pubmed: 22828611
J Immunother Cancer. 2018 Jan 22;6(1):5
pubmed: 29353553
Oncol Lett. 2016 May;11(5):3441-3445
pubmed: 27123132
Br J Cancer. 2018 Mar 20;118(6):825-830
pubmed: 29485982
Investig Clin Urol. 2019 May;60(3):176-183
pubmed: 31098425
Bratisl Lek Listy. 2017;118(9):510-512
pubmed: 29061055
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
Contrib Microbiol. 2006;13:118-137
pubmed: 16627962